Updated:
Foundation Medicine
Foundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and...
Foundation Medicine
Foundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases. We provide tests and solutions to transform care throughout a patient’s experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring. We help accelerate the development of new personalized therapies by leveraging our vast knowledge of precision medicine, real world data and AI-powered tools, expanding the information our diagnostic solutions provide to enable improved outcomes for patients. Every day, we are inspired to think differently to transform the lives of people living with cancer and other diseases. For more information, visit us at www.FoundationMedicine.com. Community Guidelines: bit.ly/FMICommunityGuidelines
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Princeton, Newark, Basel, Cambridge, Parsippany
Corporate office
—
Sector focus
Frequently asked questions
Who owns Foundation Medicine?
Foundation Medicine is a wholly owned subsidiary of Roche, the Swiss pharmaceutical giant. Roche acquired the outstanding shares in 2018 for around $2.4 billion (per The New York Times, 2018). The company operates as an independent commercial entity within Roche.
What genomic tests does Foundation Medicine offer?
The flagship test is FoundationOne CDx, a tissue-based comprehensive genomic profiling assay for solid tumors approved by the FDA as a companion diagnostic. Other tests include FoundationOne Liquid CDx for blood-based profiling and FoundationOne Heme for hematologic malignancies. FoundationOne Tracker is a liquid biopsy product for monitoring treatment response (per the firm).
How does Foundation Medicine generate revenue?
Revenue comes from two primary streams: clinical testing services sold to healthcare providers and biopharma partnerships for drug development, biomarker discovery, and clinical trial enrollment. The company also receives payments from Medicare and private insurers.
Is Foundation Medicine an investment firm or asset manager?
No. Foundation Medicine is a clinical diagnostics laboratory, not an investment firm. It does not manage third-party capital or deploy funds as a financial sponsor. Its economic model is fee-for-service testing and partnership revenue.
What does Foundation Medicine's partnership with biopharma involve?
Foundation Medicine partners with over 50 biopharma companies to develop companion diagnostics, identify biomarkers, and enable clinical trial enrollment. These collaborations provide drug developers with genomic data to match patients to targeted therapies.
How does Foundation Medicine use AI/ML?
The company applies machine learning to its database of over 600,000 de-identified genomic profiles to discover biomarkers, predict drug response, and improve test accuracy. This powers its drug development partnerships (public record).
Who is the largest shareholder of Foundation Medicine?
Roche is the sole shareholder, owning 100% of the company since 2018. Before acquisition, shareholders included Roche, Google Ventures, Third Rock Ventures, and public market investors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: